In an effort to strengthen its presence in the state of New
York, health insurer,
UnitedHealth Group Inc.
) announced its plans to recruit 150 employees in the region. These
new appointments will be made at its Tonawanda operation center,
located in the western part of New York.
The Tonawanda center was established in 2005. Via this facility,
the company issues employer sponsored and individual health plans.
Prior to this, UnitedHealth had already made 125 job appointments
in New York back in 2011. The facility's job count is
expected to reach 700 by the end of 2012.
United Health has been on a hiring spree, and it made a number of
job related announcements over the past three months. During July,
the company announced that it is about to hire 115 new employees at
its Chico operations in California.
This step was taken in order to fulfill the commitments it
made to create jobs under the "100,000 Jobs Mission" program.
Moreover in June, UnitedHealth announced its strategy to recruit
approximately 1500 employees in the state of Texas. The
appointments were made at Harlingen, San Antonio, Irving and Sugar
The company is likely to make more job additions in the near term.
It is working hard on its goal of employing more than 4000 people
in New York by the end of 2012.
UnitedHealth has a significant presence in New York with a network
of more than 230 hospitals and 43,500 physicians and care
professionals throughout the state.
The state has become an attractive destination for businesses that
are looking to expand. The State Government has made a lot of
improvements in the business climate of the region, such as
spending cut, lowering taxes as well as made it favorable for
sustainable business growth.
Other insurers having presence in New York includes
), among others.
AETNA INC-NEW (AET): Free Stock Analysis Report
CIGNA CORP (CI): Free Stock Analysis Report
UNITEDHEALTH GP (UNH): Free Stock Analysis
To read this article on Zacks.com click here.
UnitedHealth currently retains a Zacks #2 Rank, which translates
into a short-term Buy rating. We are, however, maintaining
our long-term Neutral recommendation on its shares.